Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 166

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 166
---
 )

    Non cash lease expense

    (248
    )

    (370
    )

    335

    Loss on termination of lease, net

    4,604

    —

    —

    Loss on sales and disposals of fixed assets, net

    62

    —

    —

    Other, net

    (44
    )

    —

    (92
    )

    Change in operating assets and liabilities:

    Prepaid expenses and other assets

    (2,674
    )

    1,723

    (1,829
    )

    Operating lease liabilities

    241

    837

    2,969

    Accounts payable

    3,342

    235

    (389
    )

    Accrued expenses

    (2,501
    )

    2,632

    (1,319
    )

    Net cash used in operating activities

    (51,282
    )

    (55,657
    )

    (63,760
    )

    Cash flows from investing activities:

    Purchases of property and equipment

    (655
    )

    (962
    )

    (7,984
    )

    Proceeds from sale of property and equipment

    251

    —

    —

    Purchases of marketable securities

    (148,286
    )

    (220,539
    )

    (229,199
    )

    Maturities of marketable securities

    202,042

    170,956

    235,815

    Net cash provided by investing activities

    53,352

    (50,545
    )

    (1,368
    )

    Cash flows from financing activities:

    Issuance of common stock, net of issuance costs

    —

    35,121

    —

    Proceeds from the exercise of stock options and common stock    issued under the 2020 ESPP

    313

    456

    958

    Net cash provided by financing activities

    313

    35,577

    958

    Impact of exchange rates on cash, cash equivalents, and restricted cash

    (35
    )

    34

    —

    Net increase (decrease) in cash, cash equivalents, and restricted cash

    2,348

    (70,591
    )

    (64,170